Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
March 28, 2024 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research...
Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody
December 05, 2023 08:15 ET
|
Ocean Biomedical, Inc.
Results published in the Journal Immunity share discovery of a new mechanism by which Chi3L1 regulates breast cancer development and progression PROVIDENCE, Rhode Island, Dec. 05, 2023 (GLOBE...
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
November 29, 2023 17:41 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market...
Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
October 12, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top...
Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.
August 09, 2023 08:31 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr. Jonathan Kurtis, MD, PhD on September 14, 2023 Providence, RI, Aug. ...
Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility
May 16, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, May 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
May 01, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
April 27, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Results published in peer-reviewed Cancer Research share novel insights into Chi3L1’s role in modulating Glioma stem cells and reinforces the potential therapeutic impact of Anti-Chi3L1 Providence,...
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.
April 20, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Details Novel Malaria Therapeutic Discoveries at the NIH Laboratory of Malaria Vaccinology and Immunology on PfGARP’s Potential as a Highly Effective Vaccine Target and Therapeutic Candidate to Treat Malaria
March 21, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, March 21, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc., a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from...